Dose dependence of treatment-related adverse events for immune checkpoint inhibitor therapies: a model-based meta-analysis

Boris Shulgina M&S Decisions LLC, Moscow, RussiaView further author information

Yuri Kosinskya M&S Decisions LLC, Moscow, RussiaView further author information

Andrey Omelchenkoa M&S Decisions LLC, Moscow, RussiaView further author information

Lulu Chub PK Sciences Modeling & Simulation, Novartis Institutes of BioMedical Research, Cambridge, MA, USAView further author information

Ganesh Mugunduc Clinical Pharmacology & Quantitative Pharmacology, R&D BioPharmaceuticals, AstraZeneca, Waltham, MA, USAView further author information

Sergey Aksenovc Clinical Pharmacology & Quantitative Pharmacology, R&D BioPharmaceuticals, AstraZeneca, Waltham, MA, USAView further author information

Rodrigo Pimenteld Medical Affairs, AstraZeneca, Gaithersburg, MD, USAView further author information

Garrett DeYuliad Medical Affairs, AstraZeneca, Gaithersburg, MD, USAView further author information

Geoffrey Kime Applied Innovation, BeiGene, Cambridge, MA, USAView further author information

Kirill Peskova M&S Decisions LLC, Moscow, Russia;f I.M.Sechenov first Moscow State Medical University of the Russian Ministry of Health, Moscow, RussiaCorrespondence[email protected]